KV1.3 blockade decreases cerebral amyloid load, enhances hippocampal neuronal plasticity, and improves behavioral deficits by a reduction of microglia activation and inflammatory cytokines levels in transgenic AD mouse models (Chen et al., 2018; Maezawa et al., 2018; Ma et al., 2020). This evidence concerns the gene KCNA3 and Alzheimer disease.